Ifinatamab Deruxtecan (I-DXd)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Ifinatamab Deruxtecan (I-DXd), covering 2026-04-20 to 2026-04-20. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) [Phase 1, Phase 2]